Lipid-modifying agent combination

This page covers all Lipid-modifying agent combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways, Niacin: GPR109A (hydroxycarboxylic acid receptor 2); Laropiprant: DP1 (prostaglandin D2 receptor).

Targets

DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways · Niacin: GPR109A (hydroxycarboxylic acid receptor 2); Laropiprant: DP1 (prostaglandin D2 receptor)

Marketed (1)

• Niacin plus laropiprant · Institut Investigacio Sanitaria Pere Virgili · Cardiovascular
  Niacin raises HDL cholesterol and lowers triglycerides, while laropiprant blocks prostaglandin D2 receptors to reduce niacin-induced flushing.

Phase 3 pipeline (1)

• Comparator: niacin + laropiprant · Merck Sharp & Dohme LLC · Cardiovascular
  Niacin raises HDL cholesterol and lowers triglycerides, while laropiprant blocks the prostaglandin D2 receptor to reduce niacin-induced flushing.